BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.（BMRN）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BMRN · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
4
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
BioMarin Pharmaceutical Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
BMRN 季度内部人买卖趋势
BMRN 内幕交易卖出 · BMRN 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · BMRN CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
BMRN 高管卖出股份 · BMRN 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 2, 2026 | Countouriotis Athena Director | Award | 7,490 | — | Form 4 |
| Jun 2, 2026 | Walbert Timothy P Director | Award | 7,490 | — | Form 4 |
| Jun 2, 2026 | Ho Maykin Director | Award | 7,490 | — | Form 4 |
| Jun 2, 2026 | HOMBACH ROBERT J. Director | Award | 7,490 | — | Form 4 |
| Jun 2, 2026 | Enyedy Mark J Director | Award | 7,490 | — | Form 4 |
| Jun 2, 2026 | Dere Willard H Director | Award | 7,490 | — | Form 4 |
| Jun 2, 2026 | CLARK IAN T Director | Award | 7,490 | — | Form 4 |
| Jun 2, 2026 | Bodem Barbara W. Director | Award | 7,490 | — | Form 4 |
| Jun 2, 2026 | ANDERSON ELIZABETH M Director | Award | 7,490 | — | Form 4 |
| May 20, 2026 | Hubbard Cristin EVP, Chief Commercial Officer | Other | 2,318 | $116K | Form 4 |
| May 7, 2026 | Friberg Gregory R EVP, Chief R&D Officer | Sale | 3,281 | $177K | Form 4 |
| Mar 18, 2026 | Davis George Eric EVP, Chief Legal Officer | Other | 1,273 | $71K | Form 4 |
| Mar 17, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Other | 1,693 | $95K | Form 4 |
| Mar 17, 2026 | Mueller Brian EVP, Chief Financial Officer | Other | 2,117 | $119K | Form 4 |
| Mar 17, 2026 | Hardy Alexander CEO · Director | Other | 4,252 | $238K | Form 4 |
| Mar 16, 2026 | Hubbard Cristin EVP, Chief Commercial Officer | Award | 15,410 | — | Form 4 |
| Mar 17, 2026 | Hubbard Cristin EVP, Chief Commercial Officer | Other | 1,245 | $70K | Form 4 |
| Mar 16, 2026 | Friberg Gregory R EVP, Chief R&D Officer | Award | 19,150 | — | Form 4 |
| Mar 17, 2026 | Friberg Gregory R EVP, Chief R&D Officer | Other | 1,629 | $91K | Form 4 |
| Mar 16, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Award | 14,990 | — | Form 4 |
| Mar 13, 2026 | Guyer Charles Greg EVP, Chief Technical Officer | Other | 9,109 | $533K | Form 4 |
| Mar 16, 2026 | Davis George Eric EVP, Chief Legal Officer | Award | 14,570 | — | Form 4 |
| Mar 16, 2026 | Davis George Eric EVP, Chief Legal Officer | Other | 7,177 | $420K | Form 4 |
| Mar 16, 2026 | Mueller Brian EVP, Chief Financial Officer | Award | 18,740 | — | Form 4 |
| Mar 13, 2026 | Mueller Brian EVP, Chief Financial Officer | Other | 9,945 | $582K | Form 4 |
Hubbard Cristin
EVP, Chief Commercial Officer
日期
May 20
股数
2,318
均价
$50.20
总金额
$116K
Guyer Charles Greg
EVP, Chief Technical Officer
日期
Mar 17
股数
1,693
均价
$56.05
总金额
$95K
Hubbard Cristin
EVP, Chief Commercial Officer
日期
Mar 17
股数
1,245
均价
$56.05
总金额
$70K
Guyer Charles Greg
EVP, Chief Technical Officer
日期
Mar 13
股数
9,109
均价
$58.51
总金额
$533K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BMRN 内幕交易
BMRN 内幕交易
BioMarin Pharmaceutical Inc.（BMRN）内幕交易数据来源于公司内部人（包括Davis George Eric (EVP, Chief Legal Officer), Guyer Charles Greg (EVP, Chief Technical Officer), Mueller Brian (EVP, Chief Financial Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。BMRN内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看BioMarin Pharmaceutical Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BMRN 内幕交易 · 5个问题BioMarin Pharmaceutical Inc.（BMRN）的内部人包括高管和董事，如Davis George Eric (EVP, Chief Legal Officer), Guyer Charles Greg (EVP, Chief Technical Officer), Mueller Brian (EVP, Chief Financial Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026